Cancer has become the second most lethal disease in the past several decades. Today, there is a need for the design and synthesis of more structural compounds specific to cancer-related target receptors or enzymes and their common cancer-associated mutations. Specific inhibitors and some natural product derivatives are the most critical sources of anti-tumor drugs, for example, Benzimidazole the PARP-1 inhibitor and natural derivatives such as flavonoid and Slavonic acid.
Research on the PARP-1 inhibitor has been essential and prominent over the last few years because it was found to be effective not only in the treatment of BRCA-mutated recurrent ovarian cancer and triple-negative breast cancer, but also has the potential pharmacology activities applied in non-small cell carcinoma. Currently, commercially available PARP-1 inhibitor has some adverse reactions such as anemia, leukopenia, and neutropenia and therefore safer and more effective PARP inhibitors should be explored.
Furthermore, natural products are one of the most critical sources of anti-tumor drugs and a lot of natural products and their derivatives have been widely used in clinical practice. We expect more novel natural derivatives such as flavonoid and Slavonic acid could be designed and synthesized.
This Research Topic focuses on the research carried out on the design and synthesis of novel anti-tumor agents of PARP-1 as well as their structure and functional activities. We also welcome new research on natural products associated with PARP-1 inhibition.
This Research Topic encourages authors to submit Original Research and Review articles focused on but not limited to:
? Medicinal chemistry on anti-tumor agents of PARP-1 inhibitor
? Design and synthesis and/or functional and structural analysis on the relationship between the PARP-1 inhibitor and Benzimidazole compound
? Design and synthesis and/or functional and structural analysis research on natural product derivatives
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Cancer has become the second most lethal disease in the past several decades. Today, there is a need for the design and synthesis of more structural compounds specific to cancer-related target receptors or enzymes and their common cancer-associated mutations. Specific inhibitors and some natural product derivatives are the most critical sources of anti-tumor drugs, for example, Benzimidazole the PARP-1 inhibitor and natural derivatives such as flavonoid and Slavonic acid.
Research on the PARP-1 inhibitor has been essential and prominent over the last few years because it was found to be effective not only in the treatment of BRCA-mutated recurrent ovarian cancer and triple-negative breast cancer, but also has the potential pharmacology activities applied in non-small cell carcinoma. Currently, commercially available PARP-1 inhibitor has some adverse reactions such as anemia, leukopenia, and neutropenia and therefore safer and more effective PARP inhibitors should be explored.
Furthermore, natural products are one of the most critical sources of anti-tumor drugs and a lot of natural products and their derivatives have been widely used in clinical practice. We expect more novel natural derivatives such as flavonoid and Slavonic acid could be designed and synthesized.
This Research Topic focuses on the research carried out on the design and synthesis of novel anti-tumor agents of PARP-1 as well as their structure and functional activities. We also welcome new research on natural products associated with PARP-1 inhibition.
This Research Topic encourages authors to submit Original Research and Review articles focused on but not limited to:
? Medicinal chemistry on anti-tumor agents of PARP-1 inhibitor
? Design and synthesis and/or functional and structural analysis on the relationship between the PARP-1 inhibitor and Benzimidazole compound
? Design and synthesis and/or functional and structural analysis research on natural product derivatives
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.